Real-world HIV RNA and Antigen/Antibody Testing Among People Who Use Long-acting Injectable Preexposure Prophylaxis
Clinical Infectious Diseases · 06.11.2025 · 81 (4) · e102-e107
DOI: 10.1093/cid/ciaf173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 03.04.2025. Verfasst von Weiming Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: HIV Research Branch, Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, RNA, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.
Abstract (Originalsprache)
Background
People who use long-acting injectable cabotegravir (CAB-LA) for preexposure prophylaxis (PrEP) can have ambiguous human immunodeficiency virus (HIV) test results if HIV is acquired during its use. The 2021 Centers for Disease Control and Prevention PrEP guidelines recommend both HIV antigen/antibody (Ag/Ab) and RNA testing at CAB-LA initiation and follow-up.
Methods
We conducted a cohort study using the HealthVerity database to evaluate the utilization of HIV testing among people who use CAB-LA PrEP. We identified and adjudicated HIV Ag/Ab and RNA tests with a positive result, and estimated the incidence of breakthrough HIV infection or long-acting early viral inhibition (LEVI) syndrome. Testing agreement, false-positive test rates, and positive predictive value were explored.
Results
Among 384 people who use CAB-LA PrEP with both HIV Ag/Ab and RNA testing with a median follow-up time of 4.2 months, we found 1 discordant pair with Ag/Ab negative (−) and RNA positive (+), and 1 with Ag/Ab(+) and RNA(−). Among 4 users with a positive Ag/Ab or RNA test, we identified 1 who acquired HIV before CAB-LA initiation with both Ag/Ab(+) and RNA(+), 1 likely false RNA(+), 1 likely false Ag/Ab(+), and 1 inconclusive Ag/Ab(+) due to insufficient follow-up. We identified no persons with confirmed breakthrough HIV infection or LEVI syndrome, or with RNA testing resulting in an earlier HIV diagnosis compared with Ag/Ab testing alone.
Conclusions
The frequency of breakthrough HIV infection or LEVI syndrome in this real-world cohort was low during initial 3–7 months of injectable PrEP use. Ongoing assessment of the added value of HIV RNA testing for monitoring during CAB-LA PrEP use is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV Research Branch, Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
ORCID-Profile: Weiming Zhu, Kevin Delaney, Ya-Lin A Huang, Athena P Kourtis, Karen W Hoover
Förderung
- Intramural CDC HHS
Zitieren
APA
Zhu, W., Delaney, K., Huang, Y. A., Patel, R. R., Kourtis, A. P., & Hoover, K. W. (2025). Real-world HIV RNA and Antigen/Antibody Testing Among People Who Use Long-acting Injectable Preexposure Prophylaxis. Clinical Infectious Diseases, 81(4), e102-e107. https://doi.org/10.1093/cid/ciaf173
Vancouver
Zhu W, Delaney K, Huang YA, Patel RR, Kourtis AP, Hoover KW. Real-world HIV RNA and Antigen/Antibody Testing Among People Who Use Long-acting Injectable Preexposure Prophylaxis. Clinical Infectious Diseases. 2025;81(4):e102-e107. doi:10.1093/cid/ciaf173
BibTeX
@article{Zhu2025,
author = {Zhu, Weiming and Delaney, Kevin and Huang, Ya-Lin A and Patel, Rupa R and Kourtis, Athena P and Hoover, Karen W},
title = {Real-world HIV RNA and Antigen/Antibody Testing Among People Who Use Long-acting Injectable Preexposure Prophylaxis},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {81},
number = {4},
pages = {e102--e107},
doi = {10.1093/cid/ciaf173}
}
EUVIMED